Home›Diltiazem Hydrochloride Extended-Release Tablets

Diltiazem Hydrochloride Extended-Release Tablets

Also known as: Diltiazem Hydrochloride

Route: Oral

Check Diltiazem Hydrochloride Extended-Release Tablets Interactions →

3 interactions on record

Diltiazem Hydrochloride Extended-Release Tablets has 3 known drug interactions based on U.S. FDA drug labeling data. Of these, 1 are contraindicated combinations that should be avoided entirely. 2 are classified as major interactions requiring close medical supervision. Notable interactions include combinations with Ivabradine, Digitalis Glycosides, Nonselective Beta-Adrenergic Antagonists. Patients taking Diltiazem Hydrochloride Extended-Release Tablets should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.

Total: 3
Contraindicated: 1
Major: 2

Contraindicated (1)

Diltiazem Hydrochloride Extended-Release Tablets + Ivabradine— Diltiazem increases exposure to ivabradine and may exacerbate bradycardia and conduction disturbances. Concomitant use s…

Major (2)

Diltiazem Hydrochloride Extended-Release Tablets + Digitalis Glycosides— Concurrent use may increase risk for hypotension, bradycardia, and heart failure due to impaired cardiac contractility a…
Diltiazem Hydrochloride Extended-Release Tablets + Nonselective Beta-Adrenergic Antagonists— Concurrent use may increase risk for hypotension, bradycardia, and heart failure due to impaired cardiac contractility a…

Diltiazem Hydrochloride Extended-Release Tablets + Ivabradine⛔Contraindicated

Diltiazem increases exposure to ivabradine and may exacerbate bradycardia and conduction disturbances. Concomitant use should be avoided.

Diltiazem Hydrochloride Extended-Release Tablets + Digitalis Glycosides⚠️Major

Concurrent use may increase risk for hypotension, bradycardia, and heart failure due to impaired cardiac contractility and conduction.

Diltiazem Hydrochloride Extended-Release Tablets + Nonselective Beta-Adrenergic Antagonists⚠️Major

Concurrent use may increase risk for hypotension, bradycardia, and heart failure due to impaired cardiac contractility and conduction.

Contraindications

4 CONTRAINDICATIONS Diltiazem Hydrochloride Extended-Release Tablets are contraindicated in: • Patients with sick sinus syndrome except in the presence of a functioning ventricular pacemaker. • Patients with second- or third-degree AV block except in the presence of a functioning ventricular pacemaker. • Patients with hypotension (less than 90 mm Hg systolic). • Patients who have demonstrated hypersensitivity to the drug. • Patients with acute myocardial infarction and pulmonary. • Sick sinus syndrome except in the presence of a functioning ventricular pacemaker. ( 4 ) • Second- or third-degree AV block except in the presence of a functioning ventricular pacemaker. ( 4 ) • Hypotension (less than 90 mm Hg systolic). ( 4 ) • Hypersensitivity to the drug. ( 4 ) • Acute myocardial infarction and pulmonary. ( 4 )

Pregnancy & Breastfeeding

8.1 Pregnancy Risk Summary The available data from the published literature over decades of use with diltiazem during pregnancy have not identified a drug associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. In animal reproduction studies in rats and rabbits, administration of diltiazem to pregnant animals during organogenesis at oral doses approximately 1 and 4 times the Maximum Recommended Human Dose (MRHD) of Diltiazem Hydrochloride Extended-Release Tablets produced embryofetal deaths and increased incidence of skeletal abnormalities. An increased incidence of stillbirths was noted at diltiazem doses approximately 2 times the MRHD of Diltiazem Hydrochloride Extended-Release Tablets. The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of major birth defects, loss, and other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2- 4% and 15-20%, respectively. Data Animal Data Embryofetal development studies have been conducted with diltiazem in rats and rabbits. Daily oral administration of diltiazem at 0, 17.5, 35 or 70 mg/kg to pregnant rabbits during organogenesis (gestational day 6 to 18) resulted in embryo-fetal lethality at 35 mg/kg/day (approximately 1 time the MRHD of Diltiazem Hydrochloride Extended-Release Tablets, on a mg/m 2 basis) and higher, concurrent with maternal toxicity (reduced body weight gain). Daily oral administration of diltiazem at 0, 100, 200 and 400 mg/kg to pregnant rats during organogenesis (gestation day 9 to 14) resulted in embryo-fetal lethality at 200 mg/kg/day (approximately 4 times the MRHD of Diltiazem Hydrochloride Extended-Release Tablets, on a mg/m 2 basis) and higher. These doses, in some studies, were reported to cause increased incidence of skeletal malformations (e.g. malformations of

Data sourced from U.S. FDA drug labeling via openFDA and the NIH National Library of Medicine, supplemented with a small number of well-established interactions from curated clinical references. For informational purposes only. Always consult your pharmacist or physician.